T olo t a at al t o a t olo a al Fibers & Textiles Division o t o o o at o Sales Divisions/ Innovative polymer Resins & Chemicals Technical Department Division
Manufacturing Division/ ® o at o Films Division o at o Technical Department NANOALLOY Torayca & Advanced Development Center Nano-structure Composites Division o t olo design control Electronic & Information New Projects Organic synthetic Materials Division Separation membrane Development Division chemistry Pharmaceuticals & Polymer chemistry Medical Products Division Engineering Division Fine particles Water Treatment & Biotechnology Environment Division R&D Division Affiliated Companies Nanotechnology etc. Division
Toray Industries, Inc. Integrated Annual Report 2020 35 R&D STRATEGY and ACTIVITIES FOR LIFE INNOVATION
R&D STRATEGY to be Super Nanotechnologies that have achieved improvements in the discontinuous characteristics of An Undivided R&D Organization: materials. These will first be deployed to core growth driving businesses to expand nanotechnology into a The Technology Center ¥50 billion business by fiscal 2025. At the same time, Toray Group has centralized all of its R&D functions into these Super Nanotechnologies will also be deployed to the Technology Center. Bringing together specialists new Green Innovation and Life Innovation businesses. from many fields in this undivided R&D organization makes it easier to create new innovations by integrat- LIFE INNOVATION ing technologies, and enables the Group to fully utilize its combined strength by actively exploiting techniques Expanding the Life Innovation and knowledge from many fields to solve problems in a single business area. It also enables various advanced Business with Advanced Materials materials and technologies, including those developed This section introduces the initiatives aiming the expan- for other fields, to be rapidly applied to multiple busi- sion of Life Innovation (LI) business, which contributes nesses. In addition to technology fusion and combined to enhancement of medical care, health and longevity, strength, this approach also inherits the Group’s DNA diffusion and promotion of public health, and personal of pursuit of the ultimate limits and long-term continu- safety, with a target of increasing revenue six-fold by ity. This DNA enables the Technology Center to take fiscal 2030 compared with fiscal 2013. Under “AP-G a long-term perspective in managing R&D invest- 2022,” we will advance business expansion with the ments so that there is never a shortage of themes goal of reaching ¥300 billion in revenue. Of the business, for today and seeds for tomorrow and beyond. As we position the pharmaceuticals and medical devices part of “AP-G 2022,” the Group has established businesses as in a period of incubation for the future, priority areas and major initiatives to maximize the and we will take following actions for the future growth. return on R&D investments under the direction of the In the short-term, the pharmaceutical business Technology Center as an undivided R&D organization. aims sales expansion of the oral antipruritic drug REMITCH®* overseas to grow earnings. Meanwhile, Super Nanotechnology the medical devices business will launch continuously As a core technology of Toray Group, nanotechnol- original products such as HotBalloon to the market, ogy exemplifies the pursuit of the ultimate limits. expand domestic and global sales of highly valued (or Among the various types, Toray Group considers its functionalized) dialyzers, launch and promote sales of proprietary, original technologies of NANODESIGN®, new product of dialysis machines, and enforce devel- NANOALLOY®, and Nano-layered Films (PICASUS™) opment of respiratory disease treatment columns. As